A sign seen at a recent anti-TTIP demonstration in Brussels. (Photo: Floris Van Cauwelaert/flickr/cc)
Oct 03, 2016
As E.U. and U.S. officials meet in New York this week for the 15th round of Transatlantic Trade and Investment Partnership (TTIP) negotiations, a new report warns of how the corporate-friendly, increasingly unpopular deal could "lock in" high drug prices and "help entrench a broken medical innovation system."
Specifically, the analysis explains how expanding intellectual property rules and monopoly protections for medicines, which the TTIP seeks to do, is counterproductive at a time when E.U. member states and the U.S. "are facing a looming access to medicines crisis."
According to the report:
TTIP could impede change towards affordability, needs-driven innovation and alternative incentive structures. TTIP may add to existing monopoly protections for medicines; reinforce the current trend of industry claiming trade secret protection to limit access to crucial information on medicines' safety, efficacy and development; rein in the freedom of national governments to make decisions on pricing and reimbursement to ensure affordability; and establish global standards that are harmful for developing countries.
Indeed, "Given the record level of public outrage and debate over skyrocketing medicine prices in the U.S. and Europe, it is inconceivable that a trade agreement attempts to set into stone even more pro-industry rules," said Sophie Bloemen, co-founder of the E.U.-based Commons Network, which released Monday's report (pdf) along with Health Action International, of the Netherlands, and U.S. watchdog group Public Citizen.
Doctors Without Borders/Medecins sans Frontieres has similarly warned that the Trans Pacific Partnership (TPP)--also stalled largely due to public opposition--contains "aggressive intellectual property (IP) rules that would restrict access to affordable, lifesaving medicines for millions of people."
What's more, the groups express concern that the TTIP would create more opportunities "for industry to influence national pharmaceutical policies." As the report reads:
The recently leaked text has confirmed widely held concerns that the Regulatory Cooperation chapter poses a major threat to health, safety, environmental, labor, consumer, civil and political rights, and other regulatory protections. The U.S. proposals in the Regulatory Cooperation chapter seek to export many of the worst features of U.S. rulemaking. If the United States succeeds in its project, large corporations, including pharmaceutical companies, would gain enormous power to block, slow, undermine, and repeal European regulations.
"Big Pharma expects negotiators to serve its corporate profit interests in these talks," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "Unfortunately, trade agreements have become one more mechanism for drug corporations to expand their monopoly power."
The latest round of TTIP talks, taking place October 3-7 in New York City, comes as trade ministers openly acknowledge faltering support for the secretly negotiated trade deal.
"We call upon all negotiators in New York," said Tessel Mellema, policy advisor at Health Action International, "not to lock Americans and Europeans into pharmaceutical innovation system that has been failing patients, and price gouging governments, for decades."
An Unconstitutional Rampage
Trump and Musk are on an unconstitutional rampage, aiming for virtually every corner of the federal government. These two right-wing billionaires are targeting nurses, scientists, teachers, daycare providers, judges, veterans, air traffic controllers, and nuclear safety inspectors. No one is safe. The food stamps program, Social Security, Medicare, and Medicaid are next. It’s an unprecedented disaster and a five-alarm fire, but there will be a reckoning. The people did not vote for this. The American people do not want this dystopian hellscape that hides behind claims of “efficiency.” Still, in reality, it is all a giveaway to corporate interests and the libertarian dreams of far-right oligarchs like Musk. Common Dreams is playing a vital role by reporting day and night on this orgy of corruption and greed, as well as what everyday people can do to organize and fight back. As a people-powered nonprofit news outlet, we cover issues the corporate media never will, but we can only continue with our readers’ support. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Deirdre Fulton
Deirdre Fulton is a former Common Dreams senior editor and staff writer. Previously she worked as an editor and writer for the Portland Phoenix and the Boston Phoenix, where she was honored by the New England Press Association and the Association of Alternative Newsweeklies. A Boston University graduate, Deirdre is a co-founder of the Maine-based Lorem Ipsum Theater Collective and the PortFringe theater festival. She writes young adult fiction in her spare time.
As E.U. and U.S. officials meet in New York this week for the 15th round of Transatlantic Trade and Investment Partnership (TTIP) negotiations, a new report warns of how the corporate-friendly, increasingly unpopular deal could "lock in" high drug prices and "help entrench a broken medical innovation system."
Specifically, the analysis explains how expanding intellectual property rules and monopoly protections for medicines, which the TTIP seeks to do, is counterproductive at a time when E.U. member states and the U.S. "are facing a looming access to medicines crisis."
According to the report:
TTIP could impede change towards affordability, needs-driven innovation and alternative incentive structures. TTIP may add to existing monopoly protections for medicines; reinforce the current trend of industry claiming trade secret protection to limit access to crucial information on medicines' safety, efficacy and development; rein in the freedom of national governments to make decisions on pricing and reimbursement to ensure affordability; and establish global standards that are harmful for developing countries.
Indeed, "Given the record level of public outrage and debate over skyrocketing medicine prices in the U.S. and Europe, it is inconceivable that a trade agreement attempts to set into stone even more pro-industry rules," said Sophie Bloemen, co-founder of the E.U.-based Commons Network, which released Monday's report (pdf) along with Health Action International, of the Netherlands, and U.S. watchdog group Public Citizen.
Doctors Without Borders/Medecins sans Frontieres has similarly warned that the Trans Pacific Partnership (TPP)--also stalled largely due to public opposition--contains "aggressive intellectual property (IP) rules that would restrict access to affordable, lifesaving medicines for millions of people."
What's more, the groups express concern that the TTIP would create more opportunities "for industry to influence national pharmaceutical policies." As the report reads:
The recently leaked text has confirmed widely held concerns that the Regulatory Cooperation chapter poses a major threat to health, safety, environmental, labor, consumer, civil and political rights, and other regulatory protections. The U.S. proposals in the Regulatory Cooperation chapter seek to export many of the worst features of U.S. rulemaking. If the United States succeeds in its project, large corporations, including pharmaceutical companies, would gain enormous power to block, slow, undermine, and repeal European regulations.
"Big Pharma expects negotiators to serve its corporate profit interests in these talks," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "Unfortunately, trade agreements have become one more mechanism for drug corporations to expand their monopoly power."
The latest round of TTIP talks, taking place October 3-7 in New York City, comes as trade ministers openly acknowledge faltering support for the secretly negotiated trade deal.
"We call upon all negotiators in New York," said Tessel Mellema, policy advisor at Health Action International, "not to lock Americans and Europeans into pharmaceutical innovation system that has been failing patients, and price gouging governments, for decades."
Deirdre Fulton
Deirdre Fulton is a former Common Dreams senior editor and staff writer. Previously she worked as an editor and writer for the Portland Phoenix and the Boston Phoenix, where she was honored by the New England Press Association and the Association of Alternative Newsweeklies. A Boston University graduate, Deirdre is a co-founder of the Maine-based Lorem Ipsum Theater Collective and the PortFringe theater festival. She writes young adult fiction in her spare time.
As E.U. and U.S. officials meet in New York this week for the 15th round of Transatlantic Trade and Investment Partnership (TTIP) negotiations, a new report warns of how the corporate-friendly, increasingly unpopular deal could "lock in" high drug prices and "help entrench a broken medical innovation system."
Specifically, the analysis explains how expanding intellectual property rules and monopoly protections for medicines, which the TTIP seeks to do, is counterproductive at a time when E.U. member states and the U.S. "are facing a looming access to medicines crisis."
According to the report:
TTIP could impede change towards affordability, needs-driven innovation and alternative incentive structures. TTIP may add to existing monopoly protections for medicines; reinforce the current trend of industry claiming trade secret protection to limit access to crucial information on medicines' safety, efficacy and development; rein in the freedom of national governments to make decisions on pricing and reimbursement to ensure affordability; and establish global standards that are harmful for developing countries.
Indeed, "Given the record level of public outrage and debate over skyrocketing medicine prices in the U.S. and Europe, it is inconceivable that a trade agreement attempts to set into stone even more pro-industry rules," said Sophie Bloemen, co-founder of the E.U.-based Commons Network, which released Monday's report (pdf) along with Health Action International, of the Netherlands, and U.S. watchdog group Public Citizen.
Doctors Without Borders/Medecins sans Frontieres has similarly warned that the Trans Pacific Partnership (TPP)--also stalled largely due to public opposition--contains "aggressive intellectual property (IP) rules that would restrict access to affordable, lifesaving medicines for millions of people."
What's more, the groups express concern that the TTIP would create more opportunities "for industry to influence national pharmaceutical policies." As the report reads:
The recently leaked text has confirmed widely held concerns that the Regulatory Cooperation chapter poses a major threat to health, safety, environmental, labor, consumer, civil and political rights, and other regulatory protections. The U.S. proposals in the Regulatory Cooperation chapter seek to export many of the worst features of U.S. rulemaking. If the United States succeeds in its project, large corporations, including pharmaceutical companies, would gain enormous power to block, slow, undermine, and repeal European regulations.
"Big Pharma expects negotiators to serve its corporate profit interests in these talks," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "Unfortunately, trade agreements have become one more mechanism for drug corporations to expand their monopoly power."
The latest round of TTIP talks, taking place October 3-7 in New York City, comes as trade ministers openly acknowledge faltering support for the secretly negotiated trade deal.
"We call upon all negotiators in New York," said Tessel Mellema, policy advisor at Health Action International, "not to lock Americans and Europeans into pharmaceutical innovation system that has been failing patients, and price gouging governments, for decades."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.